Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Jets trade down a spot and then take Penn State offensive tackle Olu Fashanu at No. 11 in NFL draft
Lions trade up in first round of NFL draft, take Alabama cornerback Terrion Arnold
No 10 hits back at Emmanuel Macron's jibe that the Rwanda scheme is a 'betrayal' of European values
Derrick White scores 38, Celtics top Heat 102
Police officers who Tasered 93
The federal government plans to restore grizzly bears to the North Cascades region of Washington
Columbia University extends negotiations with student protesters
Welcome to stench ground zero: The village where an unspeakable two
Almost 100,000 elderly patients endure 12